Achillion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. Co.'s focus is on its complement inhibitor platform, directed at developing small molecule compounds to be used in the treatment of immune-related diseases. The alternative pathway plays a role in a number of disease conditions including rare orphan conditions such as paroxysmal nocturnal hemoglobinuria, a blood disorder, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, both kidney diseases, as well as several more prevalent indications. We show 36 historical shares outstanding datapoints in our coverage of ACHN's shares outstanding history.
Understanding the changing numbers of ACHN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACHN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACHN by allowing them to research ACHN shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
